LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Vaxart Inc

Suletud

0.41 2.5

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.41

Max

0.41

Põhinäitajad

By Trading Economics

Sissetulek

2.1M

-12M

Müük

10M

15M

Aktsiakasum

-0.05

Kasumimarginaal

-78.927

Töötajad

105

EBITDA

3.7M

-8.6M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+614.29% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-28M

103M

Eelmine avamishind

-2.09

Eelmine sulgemishind

0.41

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2025, 23:48 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

11. mai 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

11. mai 2025, 23:45 UTC

Market Talk

Oil Rises Amid Improved Market Mood -- Market Talk

11. mai 2025, 23:38 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Aristocrat Has Significant Firepower for M&A -- Market Talk

11. mai 2025, 23:36 UTC

Market Talk

Global Markets Uncertain About US-China Trade News -- Market Talk

11. mai 2025, 23:35 UTC

Market Talk

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

11. mai 2025, 23:33 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

11. mai 2025, 23:32 UTC

Peamised uudised

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

11. mai 2025, 22:44 UTC

Market Talk

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

11. mai 2025, 22:33 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

11. mai 2025, 20:19 UTC

Peamised uudised

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

11. mai 2025, 16:00 UTC

Peamised uudised

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

11. mai 2025, 11:00 UTC

Peamised uudised

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

11. mai 2025, 08:00 UTC

Peamised uudised

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

11. mai 2025, 01:00 UTC

Peamised uudised

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

11. mai 2025, 01:00 UTC

Peamised uudised

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

10. mai 2025, 21:54 UTC

Peamised uudised

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10. mai 2025, 17:12 UTC

Peamised uudised

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10. mai 2025, 15:41 UTC

Peamised uudised

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

10. mai 2025, 12:00 UTC

Peamised uudised

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10. mai 2025, 09:30 UTC

Peamised uudised

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

10. mai 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10. mai 2025, 03:52 UTC

Peamised uudised

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9. mai 2025, 23:51 UTC

Omandamised, ülevõtmised, äriostud

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9. mai 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9. mai 2025, 21:37 UTC

Peamised uudised

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9. mai 2025, 21:10 UTC

Peamised uudised

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9. mai 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. mai 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9. mai 2025, 20:42 UTC

Peamised uudised

Stocks Get a Break From Trade Chaos -- WSJ

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnasiht

By TipRanks

614.29% tõus

12 kuu keskmine prognoos

Keskmine 3 USD  614.29%

Kõrge 4 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Vaxart Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.